QQ客服 官方微博 反馈留言

	Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies
	Qi, Junyuan; Song, Yuqin; Jiang, Bo; Li, Jianyong; Tu, Meifeng; Ping, Lingyan; Li, Zengjun; Xu, Wei; Zhu, Huayuan; Zhu, Jun
	2018
卷号	132
ISSN号	0006-4971
DOI	10.1182/blood-2018-99-110585
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6349503
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Qi, Junyuan,Song, Yuqin,Jiang, Bo,et al. Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies[J],2018,132.
APA	Qi, Junyuan.,Song, Yuqin.,Jiang, Bo.,Li, Jianyong.,Tu, Meifeng.,...&Qiu, Lugui.(2018).Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies.,132.
MLA	Qi, Junyuan,et al."Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3K delta Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies".132(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。